Zacks Research Issues Positive Outlook for Alkermes Earnings

Alkermes plc (NASDAQ:ALKS) – Zacks Research upped their Q1 2026 earnings per share (EPS) estimates for shares of Alkermes in a report issued on Tuesday, July 1st. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.39 per share for the quarter, up from their prior estimate of $0.36. The consensus estimate for Alkermes’ current full-year earnings is $1.31 per share.

A number of other brokerages also recently issued reports on ALKS. UBS Group raised Alkermes from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $33.00 to $42.00 in a research note on Tuesday, June 17th. Wall Street Zen downgraded Alkermes from a “strong-buy” rating to a “buy” rating in a research note on Monday, May 5th. Cantor Fitzgerald raised Alkermes to a “strong-buy” rating in a research note on Tuesday, May 13th. Needham & Company LLC began coverage on Alkermes in a research note on Wednesday, May 28th. They issued a “buy” rating and a $45.00 price objective on the stock. Finally, Royal Bank Of Canada boosted their price objective on Alkermes from $39.00 to $40.00 and gave the company a “sector perform” rating in a research note on Friday, May 2nd. Three analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $40.00.

Alkermes Trading Down 0.9%

NASDAQ ALKS opened at $28.75 on Wednesday. The business’s 50-day moving average price is $30.10 and its two-hundred day moving average price is $30.90. Alkermes has a 12 month low of $22.90 and a 12 month high of $36.45. The firm has a market capitalization of $4.74 billion, a PE ratio of 13.76, a price-to-earnings-growth ratio of 1.80 and a beta of 0.44.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings results on Thursday, May 1st. The company reported $0.13 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.19). Alkermes had a net margin of 23.30% and a return on equity of 27.52%. The company had revenue of $306.51 million during the quarter, compared to the consensus estimate of $307.53 million. During the same quarter last year, the firm posted $0.43 EPS. The company’s quarterly revenue was down 12.6% on a year-over-year basis.

Insider Transactions at Alkermes

In other Alkermes news, SVP Christian Todd Nichols sold 3,334 shares of the stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $31.09, for a total value of $103,654.06. Following the transaction, the senior vice president owned 86,208 shares in the company, valued at approximately $2,680,206.72. This represents a 3.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. RTW Investments LP boosted its holdings in Alkermes by 13.6% in the fourth quarter. RTW Investments LP now owns 7,557,835 shares of the company’s stock worth $217,363,000 after acquiring an additional 903,802 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Alkermes by 1.1% in the fourth quarter. Renaissance Technologies LLC now owns 5,478,728 shares of the company’s stock valued at $157,568,000 after purchasing an additional 57,697 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Alkermes by 488.6% in the first quarter. JPMorgan Chase & Co. now owns 5,234,995 shares of the company’s stock valued at $172,860,000 after purchasing an additional 4,345,523 shares in the last quarter. Baker BROS. Advisors LP lifted its holdings in shares of Alkermes by 7.2% in the first quarter. Baker BROS. Advisors LP now owns 4,483,285 shares of the company’s stock valued at $148,038,000 after purchasing an additional 301,534 shares in the last quarter. Finally, American Century Companies Inc. lifted its holdings in shares of Alkermes by 0.4% in the first quarter. American Century Companies Inc. now owns 3,465,674 shares of the company’s stock valued at $114,437,000 after purchasing an additional 14,967 shares in the last quarter. Institutional investors own 95.21% of the company’s stock.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.